Recent meetings
| Date | Commissioner / Cabinet | Topic | File |
|---|---|---|---|
| 13 Feb 2026 | Martin Seychell Deputy Director-General | Courtesy call linked to ongoing project in Rwanda | — |
| 13 Feb 2026 | Martin Seychell Deputy Director-General | Courtesy call linked to ongoing project in Rwanda | SRC |
| 10 Jul 2025 | Cecile Billaux Head of Unit | BioNTech mRNA Vaccine Manufacturing Facility in Rwanda and HDX | — |
| 10 Jul 2025 | Cecile Billaux Head of Unit | BioNTech mRNA Vaccine Manufacturing Facility in Rwanda and HDX | SRC |
| 25 Jun 2025 | Cecile Billaux Head of Unit | Global Gateway Agenda on Health | — |
| 25 Jun 2025 | Koen Doens Director-General | Global Gateway Agenda on Health | — |
| 25 Jun 2025 | Cecile Billaux Head of Unit | Global Gateway Agenda on Health | SRC |
| 25 Jun 2025 | Ekaterina Zaharieva Commissioner | - Startup and Scaleup Strategy and Scaleup Europe Fund - Life Sciences Strategy | — |
| 25 Jun 2025 | Ekaterina Zaharieva Commissioner | - Startup and Scaleup Strategy and Scaleup Europe Fund - Life Sciences Strategy | SRC |
| 25 Jun 2025 | Koen Doens Director-General | Global Gateway Agenda on Health | SRC |
| 25 Jun 2025 | Andreas Schwarz Cabinet member | - Startup and Scaleup Strategy and Scaleup Europe Fund - Life Sciences Strategy | — |
| 16 May 2025 | Martin Seychell Deputy Director-General | Vaccine development and manufacturing in Africa | — |
| 16 May 2025 | Martin Seychell Deputy Director-General | Vaccine development and manufacturing in Africa | SRC |
| 16 May 2025 | Cecile Billaux Head of Unit | Vaccine development and manufacturing in Africa | SRC |
| 16 May 2025 | Cecile Billaux Head of Unit | Vaccine development and manufacturing in Africa | — |
| 07 May 2025 | Erica Gerretsen Director | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | SRC |
| 07 May 2025 | Wolfgang Philipp Principal Adviser | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | SRC |
| 07 May 2025 | Erica Gerretsen Director | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | — |
| 07 May 2025 | Cecile Billaux Head of Unit | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | — |
| 07 May 2025 | Daphne Von Buxhoeveden Head of Unit | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | — |
| 07 May 2025 | Wolfgang Philipp Principal Adviser | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | — |
| 07 May 2025 | Martin Seychell Deputy Director-General | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | — |
| 07 May 2025 | Daphne Von Buxhoeveden Head of Unit | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | SRC |
| 07 May 2025 | Cecile Billaux Head of Unit | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | SRC |
| 07 May 2025 | Martin Seychell Deputy Director-General | Update on Mpox clinical development and R&D and manufacturing landscape for Africa | SRC |
Mission & Goals
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel investigative therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic modalities with the intent of rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates aiming to address the full continuum of cancer includes mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. Based on its deep expertise in mRNA development and in-house manufacturing capabilities, BioNTech and its collaborators are researching and developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.
EU Legislative Interests
Interactions with the European Commission regarding activities relating to mRNA drugs and vaccines, including its COVID-19 vaccine. Commission proposal for the Pharmaceutical Directive Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies (‘MAV+’) African Vaccines Manufacturing Accelerator (AVMA) European and Developing Countries Clinical Trials Partnership (EDCTP) Critical Medicines Act EU Biotech Act Health Technology Assessment (HTA)
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
AusBiotech Ltd Biotechnologie-Industrie-Organisation Deutschland e.V. (BIO Deutschland e.V.) Bundesdeutscher Arbeitskreis für Umweltbewusstes Management (B.A.U.M.) e.V. Chambre de Commerce et D’Industrie France-Amerique DECHEMA Gesellschaft für Chemische Technik und Biotechnologie e.V. econsense – Forum Nachhaltige Entwicklung der Deutschen Wirtschaft e.V. European Confederation for Pharmaceutical Entrepreneurs (EUCOPE) European Society for Medical Oncology Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V. gesundheitswirtschaft rhein-main e.V. Hessenchemie – Arbeitgeberverband Chemie und verwandte Industrien für das Land Hessen e.V. IHK - Industrie- und Handelskammer zu Berlin IHK - Industrie- und Handelskammer Halle-Dessau IHK - Industrie- und Handelskammer für Koblenz IHK - Industrie- und Handelskammer für München und Oberbayern IHK - Industrie- und Handelskammer für Rheinhessen InnoNet HealthEconomy e.V Nationales Aktionsbündnis Impfen NABI e.V. Society for Immunotherapy of Cancer The Alliance for mRNA Medicines (AMM) Verband der Chemischen Industrie e.V. (VCI) Verband Forschender Arzneimittelhersteller e.V. (VFA) Zentrale zur Bekämpfung unlauteren Wettbewerbs e.V.
Organisation Members
See above.